JAMA Network
What The Study Did: Researchers evaluated the SARS-CoV-2 spike immunoglobin (Ig) G antibody levels after one and two doses of the Pfizer/BioNTech (BNT162b2) SARS-CoV-2 mRNA vaccine in previously infected individuals compared with those without previous
infection.
Authors: James Moy, M.D., of Rush University Medical Center in Chicago, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2021.19741)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
